» Articles » PMID: 32240179

Interleukin-10 Contributes to PGE2 Signalling Through Upregulation of EP4 Via SHIP1 and STAT3

Overview
Journal PLoS One
Date 2020 Apr 3
PMID 32240179
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophage cells form part of our first line defense against pathogens. Macrophages become activated by microbial products such as lipopolysaccharide (LPS) to produce inflammatory mediators, such as TNFα and other cytokines, which orchestrate the host defense against the pathogen. Once the pathogen has been eradicated, the activated macrophage must be appropriately deactivated or inflammatory diseases result. Interleukin-10 (IL10) is a key anti-inflammatory cytokine which deactivates the activated macrophage. The IL10 receptor (IL10R) signals through the Jak1/Tyk2 tyrosine kinases, STAT3 transcription factor and the SHIP1 inositol phosphatase. However, IL10 has also been described to induce the activation of the cyclic adenosine monophosphate (cAMP) regulated protein kinase A (PKA). We now report that IL10R signalling leads to STAT3/SHIP1 dependent expression of the EP4 receptor for prostaglandin E2 (PGE2). In macrophages, EP4 is a Gαs-protein coupled receptor that stimulates adenylate cyclase (AC) production of cAMP, leading to downstream activation of protein kinase A (PKA) and phosphorylation of the CREB transcription factor. IL10 induction of phospho-CREB and inhibition of LPS-induced phosphorylation of p85 PI3K and p70 S6 kinase required the presence of EP4. These data suggest that IL10R activation of STAT3/SHIP1 enhances EP4 expression, and that it is EP4 which activates cAMP-dependent signalling. The coordination between IL10R and EP4 signalling also provides an explanation for why cAMP elevating agents synergize with IL10 to elicit anti-inflammatory responses.

Citing Articles

The heat of the battle: inflammation's role in prostate cancer development and inflammation-targeted therapies.

Sharma U, Sahu A, Shekhar H, Sharma B, Haque S, Kaur D Discov Oncol. 2025; 16(1):108.

PMID: 39891849 PMC: 11787145. DOI: 10.1007/s12672-025-01829-4.


TFF3 promotes clonogenic survival of colorectal cancer cells through upregulation of EP4 via activation of STAT3.

Yang T, Fu X, Tian R, Cui H, Li L, Han J Transl Cancer Res. 2023; 12(6):1503-1515.

PMID: 37434683 PMC: 10331714. DOI: 10.21037/tcr-22-2552.


Genome-Wide Meta-Analysis Identifies Multiple Novel Rare Variants to Predict Common Human Infectious Diseases Risk.

Gelemanovic A, Ardalic T, Pribisalic A, Hayward C, Kolcic I, Polasek O Int J Mol Sci. 2023; 24(8).

PMID: 37108169 PMC: 10138356. DOI: 10.3390/ijms24087006.


Oral route lipopolysaccharide as a potential dementia preventive agent inducing neuroprotective microglia.

Mizobuchi H Front Immunol. 2023; 14:1110583.

PMID: 36969154 PMC: 10033586. DOI: 10.3389/fimmu.2023.1110583.


Prevention of Diabetes-Associated Cognitive Dysfunction Through Oral Administration of Lipopolysaccharide Derived From .

Mizobuchi H, Yamamoto K, Yamashita M, Nakata Y, Inagawa H, Kohchi C Front Immunol. 2021; 12:650176.

PMID: 34512619 PMC: 8429836. DOI: 10.3389/fimmu.2021.650176.


References
1.
Wen A, Sakamoto K, Miller L . The role of the transcription factor CREB in immune function. J Immunol. 2010; 185(11):6413-9. PMC: 5519339. DOI: 10.4049/jimmunol.1001829. View

2.
Kashmiry A, Tate R, Rotondo G, Davidson J, Rotondo D . The prostaglandin EP4 receptor is a master regulator of the expression of PGE receptors following inflammatory activation in human monocytic cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863(10):1297-1304. DOI: 10.1016/j.bbalip.2018.07.003. View

3.
MacKenzie K, van den Bosch M, Naqvi S, Elcombe S, McGuire V, Reith A . MSK1 and MSK2 inhibit lipopolysaccharide-induced prostaglandin production via an interleukin-10 feedback loop. Mol Cell Biol. 2013; 33(7):1456-67. PMC: 3624268. DOI: 10.1128/MCB.01690-12. View

4.
Ovchinnikov D . Macrophages in the embryo and beyond: much more than just giant phagocytes. Genesis. 2008; 46(9):447-62. DOI: 10.1002/dvg.20417. View

5.
Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K . Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012; 143(2):347-55. DOI: 10.1053/j.gastro.2012.04.045. View